Aspire Biopharma Holdings (ASBP) Restructuring Costs (2024 - 2025)
Aspire Biopharma Holdings' (ASBP) quarterly Restructuring Costs came in at $395692.0 in Q2 2025, up 357.85% year-on-year from $86423.0 in Q2 2024, and up 357.85% on a QoQ basis from $86423.0 in Q2 2024.
Aspire Biopharma Holdings (ASBP) Restructuring Costs (2024 - 2025) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has 2 years of Restructuring Costs data on file, last reported at $395692.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn |
| 10 | Aspire Biopharma Holdings | 1.10 Mn | -722,113.72 | 5,750.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 395,692.00 |
| Jun 30, 2024 | 86,423.00 |